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ABSTRACT 
Recent research suggests that dopamine D3 receptors may play an important role 
in the rewarding and stimulating effects of cocaine. The purpose of the present study 
was to determine whether concurrent treatments with the putative selective dopamine 
D3 antagonist U99194A would attenuate the development of behavioral sensitization 
to cocaine. 
In two experiments, sixty-four male Wistar rats, that weighed between 250 -
300g received 7 daily treatments with one of the following drug combination: 
vehicle/vehicle, vehicle/cocaine (15mg/kg, S.C.), U99194A(0.l, or 1.0 mg/kg, 
I.P.)/vehicle U99194A/cocaine. Each rat was first injected S.C. with either ofU99194 
or vehicle and then 5 min later, each rat was injected LP. with cocaine or vehicle. Ten 
min after the second injection, each rat was tested for locomotor activity in photocell 
activity chambers (Med-Associates) for 60 min. On day eight, all rats were tested for 
activity after a challenge injection of cocaine (l 5mg/kg). On day nine, all rats were 
tested for activity after a challenge injection ofU99194A (0.1 or 1.0 mg/kg). 
The major findings were as follows: a} rats treated with cocaine alone were 
significantly more active during the pretreatment phase than rats treated with only 
vehicle; b) repeated treatments with cocaine produced behavioral sensitization; c) 
neither dose ofU99194A affected activity; d) U99194A did not attenuate the cocaine-
induced stimulation of activity; e) repeated treatment cocaine with U99914A did not 
prevent the development of behavioral sensitization to cocaine, and f) rats previously 
treated with cocaine displayed significantly greater activity after the U99194A 
challenge injection compared to rats pretreated with vehicle. 
Taken together, these findings suggest that although repeated cocaine treatments 
may result in an alteration ofD3 receptors, D3 receptor stimulation is not critical to 
the development of behavioral sensitization to cocaine. 
Accepted by: ___ ~---------- Chair 
CHAPTER 1 
INTRODUCTION 
1. Psychostimulant Drug Addiction and Behavior Sensitization 
I 
Cocaine is one of the most widely abused psychostimulant drugs (Snyder, 1996). 
Acutely, cocaine induces euphoria and heightened arousal (Robinson & Becker, 1986). 
With repeated use, however, a pattern of compulsive drug-seeking and drug-taking 
behaviors may occur, leading to psychological addiction (Robinson & Berridge, 1993; 
Robinson & Becker, 1986; Berridge & Robinson, 1995). Addicted individuals often 
experience profound anguish and despair over powers the drug has over them and find 
it extremely difficult to maintain any resolve to stop using (Robinson & Becker, 1986; 
Kalivas & Stewart, 1991). Research indicates that chronic use ofpsychomotor 
stimulants induces long-term alterations in the central nervous system and produces 
behavioral sensitization (Kalivas, Duffy, DuMars, & Skinner, 1988; Snyder, 1996). 
Behavioral sensitization to cocaine refers to the finding that the motor stimulant and 
rewarding effects of cocaine often increase with repeated use of the drug (Robinson & 
Berridge, 1993). It has been speculated that the neuroadaptations mediating this 
sensitization phenomenon may, in part,, underlie the behavioral changes produced by 
chronic cocaine abuse, including paranoia, craving and relapse (Berridge & Robinson, 
1995). Consequently, an extensive amount ofresearch has been directed at determining 
the neurochemical adaptations mediating the development and expression of behavioral 
sensitization (Robinson & Berridge 1993; Kalivas & Stewart, 1991). 
Although cocaine and other psychostimulants influence several neurochemical 
systems, neuroadaptations in the mesotelecephalic system have received the most 
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attention as the primary mechanism mediating behavioral sensitization. In an early 
review of the literature, for example, Robinson and Berridge (1993) concluded that: (1) 
Many different addictive drugs activate a common neural system, the 
mesotelencephalic dopamine system; (2) Repeated administration of many addictive 
drugs causes the dopamine system to become hypersensitive, and this is accompanied 
by a gradual and incremental increase (sensitization) in the psychomotor activating and 
incentive motivational properties of drugs; (3) The neuroadaptations underlying 
sensitization are extremely persistent; and (4) The expression of sensitization is subject 
to conditioned stimulus control. 
2. Dopamine and behavioral sensitization 
Nearly all psychostimulant drugs that produce behavioral sensitization from 
caffeine to cocaine either directly or indirectly increase neuroactivity within the 
mesencephalon dopamine system. Although there are several dopamine pathways, two 
specific pathways appear to be important for the motor-stimulating and rewarding 
effects of cocaine. These are the nigrostriatal and the mesolimbic dopamine systems 
(Kalivas & Stewart, 1991 ). 
The nigrostriatal dopamine system originates from cell bodies located almost 
exclusively on the substantia nigra pars compacta on the ventral mesencephalon and 
project to terminal fields of the neostriatum (Kalivas & Stewart, 1991 ). This system 
appears to mediate motor preparatory processes (Cooper, Bloom & Roth, 1982). 
The mesolimbic dopamine system originates from cell bodies located on the AlO 
region of the ventral tegmental area of the mesencephalon (Steketee, Striplin, Murray, 
& Kalivas, 1990). These cells project to terminal fields in the limbic system, including 
the nucleus accumbens, as well as the prefrontal cortex. Drug-induced stimulation of 
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this system produces both locomotor-activation and reward. This system is thought to 
facilitate the impact of stimulus reward association and incentive motivation processes 
(Robinson & Berridge, 1993). 
3. Dopamine receptors and behavioral sensitization to cocaine 
Within the mesencephalic dopamine system, five subtypes of dopamine receptors 
have been discovered - DI, D2, D3, D4 and D5 subtypes (Civelli, Bunzow, & Grandy, 
1993; Gingrich & Caron, 1993). Based upon similarities in molecular, biochemical, 
and pharmacological characteristics, these receptor subtypes have been classified into 
two groups; the DI-like and D2-like receptors. The DI-like receptor includes the DI 
and D5 subtypes. They are found post-synaptically and stimulate adenlate cyclase 
enzyme activity. The D2-like receptor includes D2, D3 and D4 subtypes. These are 
located both pre- and post- synaptically and inhibit the adenlate cyclase enzyme 
(Schwartz, Giros Martres, & Scokolott, 1992). The D2 receptor family has a high 
affinity for antipsychotic drugs and has been shown to be negatively coupled (D2, D3 
and D4) to the second messenger adenlate cyclase (Boutherenet, Souil, & Matres, 
1991). 
Over the past ten years, a great deal ofresearch has been directed at determining 
the involvement of specific dopamine receptors in the development of behavioral 
sensitization to psychostimulant drugs. Most of this research, however, has focused on 
the overall role of the D 1- or D2- like receptors rather than individual subtypes within 
each category because of the lack of selective compounds. That is, although a number 
of drugs have been developed that selectively stimulate or inhibit either DI- or D2-like 
receptors, only recently have compounds become available that are selective to specific 
receptors within a particular group. 
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Two strategies have been used to study the role of dopamine receptors in the 
development of behavioral sensitization. One strategy has been to determine whether 
dopamine agonists selective for a particular subtype would produce behavioral 
sensitization with repeated treatments. The second strategy has been to determine 
whether concurrent treatment with selective dopamine antagonists and a 
psychostimulant drug would prevent the development of behavioral sensitization. 
Although this research suggests the involvement of both receptor subtypes in 
behavioral sensitization, the exact mechanism remains unclear. This research will be 
reviewed in the next two sections. 
4. Dopamine agonists and behavioral sensitization 
Most psychostimulant drugs of abuse result in an increased stimulation of all 
dopamine receptors (Wise & Bozarth, 1985). For example, cocaine indirectly increases 
the synaptic availability of dopamine by blocking the dopamine transmission (Kalivas 
& Stewart, 1991 ). Similarly, amphetamine invokes the release of dopamine from pre-
synaptic membranes, resulting in an increased stimulation of all dopamine receptors 
(White, 1996; Svensson, Waters, Sonesson, & Wikstrom, 1993). Likewise, 
apomorphine produces behavioral sensitization by directly stimulating both DI- and 
D2- like receptors. As noted previously, however, dopamine agonists are available that 
are selective to either the D 1- type or D2- type of dopamine receptor. 
Although the acute effects of selective dopamine agonists differ from nonselective 
drugs such as cocaine, research indicates that these compounds can result in behavioral 
sensitization with repeated treatment. For example, the selective D !-type agonist, 
SKF38393, produces decreases of activity when administered acutely but results in 
sensitization and cross-sensitization to apomorphine after chronic administration 
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(Mattingly, Rowlett, & Lovell, 1993). This finding suggests that repeated stimulation 
ofDl-type receptors may induce behavioral sensitization. 
Like the DI-like receptor agonists, repeated treatment with D2-like receptor 
agonists also produce behavioral sensitization and cross-sensitization to 
psychostimulants. For example, repeated administration of the D2-like dopamine 
agonist bromocriptine (Hoffinan & Wise, 1992) has been shown to produce behavioral 
sensitization. Similarly, numerous studies have observed behavioral sensitization with 
repeated administration of the D2-like agonist quinpirole (e.g. Szechtman, 
Talangbayan, & Canaran, 1993; Mattingly et al., 1993). Moreover, rats sensitized to 
quinpirole display cross-sensitization to apomorphine (Mattingly et al., 1993) and 
cocaine (Henry, Hu, & White, 1998). Thus, it appears that the development of 
behavioral sensitization may develop as a result of repeated stimulation of either D 1- or 
D2- like receptors. 
5. Dopamine antagonists and behavioral sensitization 
Research with selective dopamine agonists indicates that behavioral sensitization 
may develop as a result of repeated stimulation of either D 1- or D2- like receptors. 
Although D2-receptor stimulation may induce behavior sensitization, evidence from 
research with selective dopamine antagonists suggests that D2 receptor stimulation 
may not be necessary for the development of behavior sensitization. For example, 
although concurrent treatment with the D2-like DA antagonist sulpiride blocks the 
acute effect of apomorphine, it does not block the development of sensitization to 
apomorphine (Mattingly, Rowlett, Graff, & Hatton, 1991). Similarly, the development 
of behavioral sensitization to amphetamine is not affected by concurrent treatment with 
the D2-type antagonists pimozide, metoclopromide, or R0-22-2586 (Drew & Glick, 
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1990; Stewart & Vezina, 1989). In contrast, concurrent treatment with the Dl- like DA 
antagonist SCH23390 prevents the development of behavioral sensitization to both 
apomorphine (Mattingly et al., 1991) and amphetamine (Vezina & Stewart, 1989). 
Moreover, evidence indicates that concurrent treatment with SCH23390 also blocks the 
development of behavioral sensitization to the D2-like DA agonist quinpirole 
(Mattingly et al., 1993), and bromocriptine (Hoffinan & Wise, 1992). Taken together 
with the DA agonist results, these findings suggest that although D2 receptor 
stimulation may contribute to the development of behavioral sensitization to 
apomorphine and amphetamine, DI receptor stimulation is essential (Mattingly et al. 
1991, 1993). 
It has generally been assumed that the development of behavioral sensitization to 
different drugs is mediated by a common neurochemical mechanism (Robinson & 
Berridge, 1993; Kalivas & Stewart, 1991). Based upon research with amphetamine and 
apomorphine, this mechanism appeared to be related to stimulation of DI receptors. 
However, recent research with cocaine questions this assumption. For example, 
although concurrent treatment with the Dl-like DA antagonist SCH23390 prevents the 
development of behavioral sensitization to apomorphine (Mattingly et al., 1993) and 
amphetamine (Vezina & Stewart, 1989), SCH23390 treatments do not block the 
development of behavioral sensitization to cocaine (Mattingly, Hart, Lim, & Perkins, 
1994; White, Joshi, Koeltzow, & Hu, 1998). This finding suggests that unlike 
apomorphine and amphetamine, stimulation of DA DI-like receptor is not necessary to 
the development of behavioral sensitization to cocaine. 
Although SCH23390 treatment does not prevent cocaine-induced behavioral 
sensitization, concurrent treatment with the relatively non-selective dopamine 
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antagonist haloperidol does attenuate the development of behavioral sensitization to 
cocaine (Mattingly, Rowlett, Ellison, & Rase, 1996). Whether this haloperidol-induced 
attenuation of cocaine sensitization is due to blocking different DA receptors or a 
combination of DA receptors is currently unknown. 
6. Dopamine D3 receptor and behavioral sensitization 
As noted previously, three individual dopamine receptors (D2, D3, D4) have been 
classified as D2-like receptors. Until recently, little was known about the behavioral 
functions of these individual receptors because of the lack of highly selective drugs. 
Recently, however, several compounds have become available that appear to be 
relatively selective for dopamine D3 receptors (Sokoloff, Giros, Martres, Bouthentet, & 
Schwartz, 1990). Based upon research with these compounds, the D3 receptor has 
received a great deal of attention as a possible target for the treatment of cocaine abuse. 
Unlike D2 receptors, D3 receptors appear to be preferentially located in limbic 
regions of the brain closely associated locomotor activation and reward (Levesque, 
Diaz, Pilon, & Martres, 1992), and the number of binding sites for D3 receptors are 
significantly elevated in cocaine overdose victims (Staley & Mash, 1996). In addition, 
7-OH-DPAT, a putative selective agonist for D3 receptors has been reported to: a) 
attenuate cocaine self-administration in rats at doses not self-administrated (Caine & 
Coob, 1993; Nader & Mash, 1996); b) substitute for cocaine, amphetamine, and 
apomorphine in drug discrimination tasks (Khroyan, Fuch & Beck, 1999; Depoortere, 
Perrault & Sanger, 1999) and c) attenuate the incentive motivational properties of 
amphetamine, cocaine, and morphine as measured by conditioned place preference 
tests (Khroyan et. al.,1995; 1998, 1999; DeFonseca, Martin, Caine, & Nauarro, 1995). 
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Based upon these findings, it has been suggested that D3 receptors may be involved in 
the development and maintenance of drug craving. 
Dopamine D3 receptors have also been related to the development of craving as 
measured by the development of behavioral sensitization. For example, although 
administration of7-OH-DPAT decreases activity when administrated acutely, the 
repeated administration high doses of7-OH-DPAT produces behavioral sensitization 
(Mattingly, Fields, Langfels, Rowlett, & Robinet, 1996). However, unlike other 
dopamine D2-type agonist, repeated treatments with 7-OH-DPAT does not increase 
basal dopamine synthesis, which suggests that autoreceptor sensitivity is not affected 
by repeated 7-OH-DPAT treatments (Svensson, Carlsson, & Waters, 1994). In 
addition, like cocaine, concurrent treatments with the dopamine DI antagonist, 
SCH23390, does not prevent development of behavioral sensitization to 7-OH-DPAT 
(Mattingly, Himmler, Bonta, & Rice, 1998). These latter findings suggest that the 
development of behavioral sensitization to cocaine and 7-OH-DPAT may be mediated 
by a common neurochemical mechanism. Consistent with this possibility, recent 
evidence indicates that the co-treatment ofrats with a low dose of7-OH-DPAT and 
cocaine enhances the development of behavioral sensitization to cocaine (Mattingly, 
Caudill, & Abel, in press) 
7. Summary and purpose 
In summary, a great deal of evidence suggests that dopamine receptor stimulation is 
necessary for the development of behavioral sensitization to psychostimulant drugs. 
Although the development of behavioral sensitization to different psychostimulant 
drugs has been assumed to be mediated by common neurochemical mechanisms, 
research with selective dopamine D 1- and D2-like receptor antagonists questions this 
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assumption. Specifically, it has been found that the development of behavioral 
sensitization to cocaine unlike apomorphine and amphetamine, is not prevented by 
concurrent treatments with either D 1- or D2-type antagonists. Recent research suggests 
that dopamine D3 receptors may play an important role in cocaine abuse and the 
development of behavioral sensitization to cocaine. Moreover, it has been found that 
low doses of the selective dopamine D3 agonist 7-0H-DPATenhance the development 
of behavioral sensitization to cocaine. 
The major objective of the present research, therefore, was to further study the role 
of D3 receptors in the development of behavioral sensitization to cocaine by 
determining whether the co-administration the putative selective dopamine D3 receptor 






Sixty-four male Wistar albino rats (Harlan, Spraque Dawley, Indianapolis, IN) 
served as subjects in two experiments. The rats weighed between 258-297g prior to 
testing. They were housed individually in standard wire-mesh cages in a temperature-
controlled colony room with a 12 hr light-dark cycle. All testing was conducted during 
the light phase of the cycle. The rats were housed in the colony room for at least one 
week prior to the beginning of the experiment. Food and water were available 
continuously. 
Apparatus 
In both experiments, activity was measured in four open field chambers (Med-
Associates model OFA-163, see Figure 1), and each chamber was located in an 
individual sound attenuated experimental cubicle. These chambers were 41 x 41 cm., 
and had 16 x 16 array of infrared photocell beams placed 2.5cm above the floor and 
another 16 photo beams and detectors located 10 cm above the floor. A clear 
cylindrical acrylic chamber was positioned inside the outer square chamber. Output 
from each individual photocell array was connected to a Gateway-2000 (P5-75) 
Microcomputer through a Med-Associates interface, located in an adjacent room. 
Using Med-Associates software, distance traveled (cm), number ofrears, and 
stereotypy counts (small movements) were recorded at 15-min intervals. 
Drugs 
In both experiments, cocaine hydrochloride (N.I.D.A.) and U99194A 
II 
Figure 1 · Med-Associates locomotor activity testing chambers 
(Research Biomedicals) were dissolved in distilled water and injected in a volume of I 
ml/kg. Cocaine was injected LP. and U99194A was injected S.C. All drug dosages 
were calculated based upon salt weight of the drug. Vehicle injections were given 
using the same route and volume as the corresponding drug injection. 
Design and Procedure 
The design of the experiment I was a 2 (Cocaine dose: 0 or !Smg/kg) x 2 
(U99 l 94A dose: 0 or 0.1 Omg/kg) factorial design (see Table I). All rats were 
randomly assigned and to one of the four pretreatment groups. The counterbalancing 
Procedure is depicted in Appendix B. 
Table 1: Experimental Design: 
Pretreatment groups (2 x 2 Factorial Design) 
First injection (S.C.) 
U99194A 
VEHICLE 








Experiment 1 was conducted in two phases: a pretreatment phase, followed by 
challenge tests. During the pretreatment phase, the rats were first injected S.C. with 
vehicle or U99194A (0.10 mg/kg) followed 10 min later by an injection LP. with either 
vehicle or cocaine (1 Smg/kg). Five min after the cocaine injection, the rats were put 
into the activity chamber for 60 min and tested for locomotor activity. This pre-
treatment phase was repeated for seven days. 
The challenge tests were conducted on two consecutive days beginning twenty-
four hours after the pre-treatment phase. The first test was a cocaine challenge test to 
test for behavioral sensitization. The second one was a U99194A challenge test. The 
procedures were the same as during the pre-treatment phase of the experiment except 
(4e first injection was vehicle and the second injection was either cocaine (15mg/kg) or 
U99194A (0.!0mg/kg). 
In experiment 2, the design was the same as experiment 1: 2 (Cocaine dose 0 or 
15mg/kg) X 2 (U99194A dose 0 or 1.0 mg/kg) factorial design. The procedure was 
exactly the same as experiment 1, but the dose ofU99194A was I.0mg/kg. 
13 
Data Analysis 
In both experiments, significant differences among the groups in mean distance 
traveled, rears, and stereotypy during the pretreatment phase were analyzed using 
mixed four factor analyses of variance (ANOVAs) using drug treatment conditions as 
between factors and test session, and blocks of 15 min within sessions as repeated 
measures. Significant interactions were analyzed with additional ANOVAs performed 
on individual session and/or block data, followed by Newman-Keuls post hoc tests. 
Mean distance traveled, rears, and stereotypic counts of the groups on the challenge 
tests were analyzed using mixed three factor ANOV As. 
CHAPTER3 
RESULTSOFEXPERIMENTI 
Pretreatment Sessions: Day 1-7 
Distance Traveled: 
14 
The mean distance traveled (in m) for each of the four pretreatment groups across 
the four 15 min blocks of sessions 1,4, and 7 is presented in Figure 2. A summary of 
the ANOV A performed on all seven sessions is presented in Table 2. As may be seen 
in Figure 2, repeated treatment with cocaine (15mg/kg) produced a progressive 
increase in distance traveled across sessions, cocaine effect: !:(1,28) = 210.91, g <.001; 
Cocaine x Session interaction, !:( 6,168) = 16.52, g < .001; but a decrease across blocks 
within each session, Cocaine x Block interaction: !:(3,84) = 126.94, g<0.001. The 
cocaine-induced increase in activity across session was greatest on the early blocks of 
each session, Cocaine x Session x Block interaction: !:(18,504) = 8.87, g < .001. 
Repeated treatments with U99194A (0.lmg/kg) did not significantly affect distance 
traveled across the sessions or blocks within each session, U99194A effect: !:(1,28) = 
2.23, g = 0.147; U99194A x Session interaction: !:(6,168) < 1.00; U99194A x Block 
interaction: !:(3,84) = 1.39, g = 0.252; U99194A x Session x Block interaction: 
!:(18,504) < 1.00. U99194A did not significantly affect cocaine-induced changes of 
distance traveled. 
Rears: 
The mean number ofrears for the four treatment groups across the four 15 min 
blocks of sessions 1, 4, and 7 is presented in Figure 3. A summary of the ANOVA 
performed on the seven sessions is presented in Table 3. Overall, cocaine treatments 



























BLOCKS OF 15 MIN WITHIN EACH SESSION 
Figure 2.Mean distance tra1.eled (± SEM) across blocks of 15 min on sessions1,4, and 7 for rats treated 15 min 
before each session with either vehicle (VEH), or 15 mg/kg cocaine (COC) and 5 min before each session with 
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BLOCKS OF 15 MIN WITHIN EACH SESSION 
Figure 3. Mean number of rears(± SEM) across blocks of 15 min on sessions1 ,4, and 7 for rats treated 
15 min before each session with either vehicle (VEH), or 15 mg/kg cocaine (COC) and 5 min before 
each session with either vehicle (VEH) or 0.10 mg/kg U99194A 
-"' 
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effect: E(l,28) = 52.10, g < .001. However, this cocaine induced increase in reading 
decreased across both session and blocks, Cocaine x Block interaction: E (3,84) = 9.02, 
g<.001; Cocaine x Session x Block: F=2.0l, p<0.01. U99194A did not significantly 
affect rearing behavior, U99194A effect: ;E(l,28) < 1.00; U99194A x Block: E(3,84) 
<1.00. U99194A x Session interaction: E(6,168) < 1.00. More important, U99194A did 
not significantly affect cocaine-induced changes in rearing behavior, Cocaine x 
U99194A interaction: F(l, 28) < 1.00. 
Stereotypy: 
Figure 4 displays the mean stereotypic counts for the four pretreatment groups 
during sessions 1,4, and 7. A summary of the ANOV A performed on the seven sessions 
is presented in Table 4. As may be seen in Figure 4, similar to the distance traveled and 
rearing results, cocaine produced an overall increase in stereotypic counts, but a 
decrease across blocks within each session during the pretreatment sessions, cocaine 
effect: E(l,28) = 446.71, g< .001; Cocaine x Block interaction: ;E(3,84) = 19.23, g< 
.001. Stereotypic counts remained stable across sessions for cocaine treated rats, but 
declined across sessions for rats not treated with cocaine, Cocaine x Session effects: 
!':(6,168) = 8.89, g < .001. U99194A did not significantly affect the stereotypy, and 
there was no significant interactions between U99194A and cocaine, U99194A and 
session, U99194A and block, U99194A effect: ;E(l,28) <1.0; U99194A x Cocaine 
interaction: ;E(l,28) < 1.00; U99194A x Session interaction: !':(6,168) = 2.03, g> .05; 
U99194A x Blocks interaction: E(3,84) <1.00; U99194A x Session x Blocks 
interaction: !':(18,504) <1.00. U99194A did not significantly affect cocaine-induced 
increases of stereotypy. 
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BLOCKS OF 15 MIN WITHIN EACH SESSION 
Eiguc.e.A. Mean stereotypic count(± SEM) across blocks of 15 min on sessions1 ,4, and 7 for rats treated 
15 min before each session with either vehicle (VEH), or 15 mg/kg cocaine (COC) and 5 min before each 
session with either vehicle (VEH) or 0.10 mg/kg U99194A 
-00 
Sensitization Test Session 8: Cocaine Challenge Test 
Distance traveled: 
Figure 5 displays the mean distance traveled for the four pretreatment groups 
19 
after a l 5mg/kg dose of cocaine. A summary of the ANOV A performed on this data is 
presented in Table 5. Overall, as may be seen in the left panel, prior treatment with 
cocaine with or without U99 l 94A significantly increased subsequent behavioral 
sensitivity to the activating effects of the cocaine injection, cocaine effect: .!:(1,28) = 
21.79. g< .001. More important, prior treatments with U99194A (0.lmg/kg) alone did 
not significantly affect subsequent sensitivity to cocaine, and the concurrent treatments 
ofU99194A and cocaine did not block the development of sensitization to cocaine, 
U99194Aeffect: f< 1.00; U99194A x Cocaine interaction: f<l.00. However, as shown 
in the right panel, although all groups tended to decrease activity across blocks, block 
effect: !'.(3,84) = 149.05, g< .001, this decrease was greater for rats previously treated 
with cocaine, Cocaine x Block interaction: !'.(3,84) = 9.86, g< .001. There were no 
interactions among U99194A, cocaine and block factors, U99194A x Cocaine x Block: 
F< 1.0. 
Rears: 
Figure 6 displays the mean number of rears for the four pretreatment groups after 
l 5mg/kg dose of cocaine. A summary of the ANOV A performed on this data is 
presented in Table 6. As may be seem in the left panel, pretreatment with neither 
cocaine nor U99 l 94A significantly affected subsequent sensitivity to a challenge 
injection of cocaine, cocaine effect: .!:(1,28) < 1.0; U99194A effect: :E(l,28) > 1.0, 
U99194A x Cocaine interaction, :E < 1.0. All groups appeared to decrease sensitivity 
-~ 16 -C 
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COCAINE CHALLENGE TEST 
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VEH-VEH VEH-COC U99194-VEH U99194-COC 15 30 45 60 
PRETREATMENT CONDITIONS BLOCKS OF 15 MINUTES 
Eigure 5. Mean distance traveled(± SEM) after a cocaine challenge inj3ction (session 8) for rats pre1.1ously treated 
chronically 'I.1th either vehicle (VEH) or cocaine ( 15 rrg/kg COC) in combination with either vehicle (VEH) or U99194A 
(0.10 mg/kg). The left panel represents the total session acti1.1ty and the right panel presents the same data as a 





















VEH-VEH VEH-COC U99194-VEH U99194-COC 
PRETREATMENT CONDITIONS 
15 30 45 60 
BLOCKS OF 15 MINUTES 
Eigure..6. Mean number of rears(± SEM) after a cocaine challenge injection (session 8) for rats pre1fously treated 
chronically with either vehicle (VEH) or cocaine (15 rrg/kg COC) in combination with either vehicle (VEH) or U99194A 
(0.10 rrg/kg). The left panel represen1s the total session activity and the right panel presents the same data as a function 
of four 15 nin blocks within the session 
across blocks, block effect, ):(3,48) = 25.70, p_<.001, but there were no significant 
interactions between them. 
Stereotypy: 
22 
Figure 7 displays the mean number of stereotypic counts for the four pretreatment 
groups after a 15mg/kg dose of cocaine. A summary of the ANOVA performed on this 
data is presented in Table 7. As may be seen in the left panel, pretreatment with neither 
cocaine nor U99194A significantly affected subsequent sensitivity to a challenge 
injection ofcocaine, cocaine effect: ):(1,28) = 1.70, p_=.203; U99194A effect: l:(1,28) < 
1.00; U99194A x Cocaine interaction: l:(1,28) < 1.00, the changes did not obviously 
vary across the pretreatment groups, U99194A x Block: ):(3,84) < 1.0; Cocaine x Block 
interaction: l:(3,84) = 2.82, p_ = .044; U99194A x Cocaine x Block interaction ):(3, 84) 
= 1.80, p_ >= .153. Thus, pretreatment with cocaine did not result in behavioral 
sensitization using stereotypic counts as a behavioral measure. 
Sensitization Test Session 9: U99194A Challenge Test 
Distance Traveled: 
Figure 8 displays the mean distance traveled for the four pretreatment groups 
after a 0.10 mg/kg dose ofU99194A. A summary of the ANOVA performed on this 
data is presented in Table 8. Overall, as may be seen in the left panel, prior treatment 
with cocaine significantly increased subsequent behavioral sensitivity to the activating 
effects of the U99194A challenge injection, cocaine effect: l:(1,28) = 19.53, p_<.001. 
This increased response to the U99194A challenge injection in cocaine pretreated rats, 
decreased across blocks, block effect: F(3,83)=80.76, p<.001; Cocaine x Block 
interaction: F(3,84)=7.42, p<.001. Prior treatments with U99194A alone did not 
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15 30 45 60 
BLOCKS OF 15 MINUTES 
Eigure_Z. Mean stereotypic counts(± SEM) after a cocaine challenge injection (session 8) for rats prel.iously treated 
chronically with either vehicle (VEH) or cocaine (15 mg/kg COC) in combination with either vehicle (VEH) or U99194A 
(0.10 mg/kg). The left panel represents the total session activity and the right panel presents the same data as a function 


















U99194 CHALLENGE TEST 
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VEH-VEH VEH-COC U99194-VEH U99194-COC 15 30 45 60 
PRETREATMENT CONDITIONS BLOCKS OF 15 MINUTES 
' ' ' 
Figure 8 Mean distance of traveled (± SEM) after a U99194A challenge injection (session 8) for rats prelhously treated 
chronically with either 1.ehicle (VEH) or cocaine (15 mg/kg COC) in combination with etther vehicle (VEH) or U99194A 
(0.10 mg/kg). The left panel represents the total session activtty and the right panel presents the same data as a function of 
four 15 min blocks within the session 
significantly affect subsequent sensitivity to U99194A. U99194A effect: .E(l,28) < 
1.00; U99194A x Cocaine interaction:!'. (3,84)< 1.00. 
Rears: 
25 
Figure 9 displays the mean number ofrears for the four treatment groups after 
0.10 mg/kg dose ofU99194A. A summary of the ANOVA performed on this data is 
presented in Table 9. As may be seen in the left panel, pretreatment with cocaine 
significantly increased subsequent sensitivity to a challenge injection ofU99194A, 
cocaine effect: .E(l,28) = 12.3, g<.005. More important, this cocaine-induced increased 
increase was the same for rats also pretreated with vehicle or U99194A, U99194A x 
Cocaine interaction: .E(l ,28) < 1.00. However, as shown on the right panel, all groups 
appeared to decrease sensitivity across blocks, block effect: .E(3,84) = 44.11, g<.001, 
but there were no interactions between U99194A and block, cocaine and block, 
U99194A, cocaine and block factors, U99194A x Block: !'.(3,84) < 1.00; Cocaine x 
Block: !'.(3,84) = 1.34, g=.268; U99194A x Cocaine x Block interaction: .E(3,84)<1.00. 
U99194A pretreated alone did not significantly affect subsequent sensitivity to the 
U99194A challenge injection, U99194A effect: F(l,28)<1.0. 
Stereotypy: 
Figure 10 displays the mean number of stereotypic counts for the four 
pretreatment groups after a 0.10 mg/kg dose ofU99194A. A summary of the ANOVA 
performed on this data is presented in Table 10. As may be seen in the left panel, 
pretreatment with cocaine increased the subsequent sensitivity to a challenge injection 
ofU99194A, but pretreatment with U99194A did not significantly affect subsequent 
sensitivity to a challenge injection ofU99194A, U99194A effect: !'.(1,28)=1.15, g>.05; 
cocaine effect: .E(l,28) = 15.43, g< .001; U99194A x Cocaine interaction: 
26 
E(l,28)<1.00]. Stereotypic counts significantly decreased across the blocks, block 
effect: !:(3,84) = 65.44, 2<.001. There were no significant interactions between 
U99194A and block, cocaine and block, U99194A, cocaine and block factors, 
U99194A x Block interaction: !'.(3,84) < 1.00; Cocaine x Block interaction: !:(3,48) = 
1.03, 2=0.386; U99194A x Cocaine x Block interaction: !'.(3,84) < 1.00]. 
U99194 CHALLENGE TEST 
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VEH-VEH VEH-COC U99194-VEH U99194-COC 15 30 45 60 
PRETREATMENT CONDITIONS BLOCKS OF 15 MINUTES 
EiguceJL Mean number of rears(± SEM) after a U99194A challenge injection (session 8) for rats previously treated 
chronically with either vehicle (VEH) or cocaine (15 mg/kg COC) in combination with either 1.ehicle (VEH) or U99194A 
(0.10 mg/kg). The left panel represents the total session activity and the right panel presents the same data as a 















U99194 CHALLENGE TEST 
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15 30 45 60 
BLOCKS OF 15 MINUTES 
Eigure.10. Mean stereotypic counts (± SEM) after a U99194A challenge injection (session 9) for rats previously treated 
chronically 1Mth either 1.ehicle (VEH) or cocaine (15 mg/kg COG) in corrbination 1Mth either vehicle (VEH) or U99194A 
(1.00 mg/kg). The left panel represents the total session activity and the right panel presents the same data as a function 




RESULTS OF EXPERIMENT 2 
Pretreatment Sessions- Day 1-7 
Distance Traveled: 
29 
The mean distance traveled in meters for each of the four pretreatment groups 
across the four 15 min blocks of session 1,4, and 7 is presented in Figure 11. A 
summary of the ANOV A performed on all seven sessions is presented in Table 11. As 
may be seen in Figure! 1, repeated treatment with cocaine (15mg/kg) produced a 
progressive increase in distance traveled across sessions and a decrease across blocks 
within each session, cocaine effect: !:(1,28) =155.61, g < .001; Cocaine x Session 
interaction, _!'.(6,168) = 10.32, g <.001; Cocaine x Session x Block interaction: 
_!'.(18,504) = 5.12, g < .001. Repeated treatments with U99194A (l.0mg/kg) did not 
affect distance traveled across sessions or blocks within each session, U99 l 94A effect: 
.E(l,28) = 1.84, g = .185; U99194A x Session interaction: !'.(6,168) < 1.0; U99194A x 
Block interaction: !:(3,84) = 2.06, g = .111; U99194A x Session x Block interaction: 
!:(18,504) < 1.0. U99194A did not significantly affect cocaine-induced changes of 
distance traveled. 
Rears: 
The mean number of rears for the four treatment groups across the four 15 min 
blocks of sessions 1, 4, and 7 is presented in Figure 12. A summary of the ANOV A 
performed on the seven sessions is presented in Ta~le 12. Overall, cocaine treatments 
significantly increased rearing behaviors during the pretreatment sessions, cocaine 
effect: _E(l,28) = 194.58, g < .001. The effects ofcocaine (15mg/kg) treatments 
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BLOCKS OF 15 MIN WITHIN EACH SESSION 
Eigure 11.Mean distance tra11eled (± SEM) across blocks of 15 min on sessions1 ,4, and 7 for rats treated 15 min 
before each session with either vehicle (VEH), or 15 mg/kg cocaine (COC) and 5 min before each session with 
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BLOCKS OF 15 MIN WITHIN EACH SESSION 
Figure 12. Mean number of rears(± SEM) across blocks of 15 min on sessions1 ,4, and 7 for rati; 
treated 15 min before each session with either vehicle (VEH), or 15 mg/kg cocaine (COC) and 5 min 
before each session with either vehicle (VEH) or 1.00 mg/kg U99194A 
vJ -
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2<.001, and cross sessions on some blocks, Cocaine x Session x Blocks interaction, 
F(l8, 504)=2.09, p<.01. Overall, U99194A did not significantly affect rearing 
behaviors, U99194A effects: f(l,28) < 1.00, but it did appear to enhance the cocaine-
induce increase in rearing behavior, U99194A x Cocaine interaction: F(l,28)=10.21, 
p<.0 I. There was no interaction between U99 l 94A and sessions or U99 l 94A and 
blocks, U99194A x Session interaction: .!'.(6,168) < 1.00; U99194A x Block interaction: 
.!'.(3,84) < 1.00. 
Stereotypy: 
Figure 13 displays the mean stereotypic counts for the four pretreatment groups 
during sessions 1,4, and 7. A summary of the ANOV A performed on the seven sessions 
is presented in Table 13. As may be seen in Figure 13, similar to the distance traveled 
and rearing results, cocaine produced an increase in stereotypic counts across sessions 
and a decrease across blocks within each session, cocaine effect: .E(l,28) = 510.35, 2< 
.001; Cocaine x Session effects: _E(6,168) = 5.62, 2 < .001; Cocaine x Block interaction: 
.!'.(3,84) = 14.93, 2< .001. U99194A had no significant effect, and there was no 
significant interactions between U99 l 94A and cocaine, U99 l 94A and sessions, 
U99194A and blocks, U99194A effect: .E(l,28) =2.32, 2=.139; U99194A x Cocaine 
interaction: .E(l,28) < 1.00; U99194A x Session interaction: .!'.(6,168) < 1.00; U99194A 
x Block interaction: .!'.(3,84) = 1.77, :[!= .159; U99194A x Session x Block interaction: 























BLOCKS OF 15 MIN WITHIN EACH SESSION 
Eigure 13. Mean stereotypic count(± SEM) across blocks of 15 min on sessions1 ,4, and 7 for rats treated 
15 min before each session with either vehicle (VEH), or 15 mg/kg cocaine (COC) and 5 min before each 
session with either vehicle (VEH) or 1.00 mg/kg U99194A 
t;.> 
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Sensitization Test Session 8: Cocaine Challenge Test 
Distance traveled: 
34 
Figure 14 displays the mean distance traveled for the four pretreatment groups 
after a l 5mg/kg dose of cocaine. A summary of the ANOV A performed on this data is 
presented in Table 14. Overall, as may be seen in the left panel, prior treatment with 
cocaine with or without U99194A significantly increased subsequent behavioral 
sensitivity to the activating effects of the cocaine injection, cocaine effect: !'.(1,28) = 
55.44. g< .001. More important, prior treatments with U99194A alone did not 
significantly increase subsequent sensitivity to cocaine, and the concurrent treatments 
ofU99194A and cocaine did not block the development of sensitization to cocaine, 
U99194A effect: ;E< 1.00; U99194A x Cocaine interaction: ;E<l.00. However, as show 
on the right panel, all groups tended to decrease activity across blocks, block effect: 
!'.(3,84) =76.92, g< .001. The cocaine effect decreased across blocks, Cocaine x Block 
interaction: !'.(3,84) = 31.08, g< .001. 
Rears: 
Figure 15 displays the mean number of rears for the four pretreatment groups 
after l 5mg/kg dose of cocaine. A summary of the ANOV A performed on this data is 
presented in Table 15. As may be seen in the left panel, pretreatment with cocaine 
significantly increased subsequent sensitivity to a challenge injection of cocaine, but 
U99194A did not significantly affect subsequent sensitivity to a challenge injection of 
cocaine, cocaine effect: !'.(1,28) =6.58, g=0.016; U99194A effect: !'.(1,28) <1.00. More 
important, concurrent pretreatment with cocaine and U99194A (l .0mg/kg) did not 
block the development ofbehavioral sensitization to cocaine, U99194A x Cocaine 
interaction:]:< 1.0. All groups appear to decrease sensitivity across blocks, but there 







O 80 z 
<C 
~ -





COCAINE CHALLENGE TEST 
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VEH-VEH VEH-COC U99194-VEH U99194-COC 15 30 45 60 
PRETREATMENT CONDITIONS BLOCKS OF 15 MINUTES 
Eigure-1A. Mean distance traveled(± SEM) after a cocaine challenge injection (session 8) for rats previously treated 
chronically with either vehicle (VEH) or cocaine (15 mg/kg COC) in combination with ei1her vehicle (VEH) or U99194A 
(1.00 mg/kg). The left panel represents the total session activity and the right panel presents the same data as a 
function of four 15 min blocks within the session 
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COCAINE CHALLENGE TEST 
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BLOCKS OF 15 MINUTES 
Eigur:e.15. lvlean number of rears(± SEM) after a cocaine challenge injection (session 8) for rats prel.iously treated 
chronically with either vehicle (VEH) or cocaine (15 mg/kg COC) in combination with either vehicle (VEH) or U99194A 
( 1.00 mg/kg). The left panel represents the total session activity and the right panel presents the same data as a function 




were no interactions between cocaine and block factors, U99194A and block factors, 
block effect: !'.(3,84)=33.15, g<.001. Cocaine appeared to increase rears on block I and 
2, compared with the rats in vehicle group, but U99194A appeared to decrease rears on 
block 3 and 4,.U99194A x Cocaine x Block interaction, !'.(3,84)=3.40, g<.05. There 
was no interaction between U99194A and block factors, U99194A x Block 
!'.(3,84)=0.47, g=.702. 
Stereotypy: 
Figure 16 displays the mean number of stereotypic counts for the four 
. pretreatment groups after a 15mg/kg dose of cocaine. A summary of the ANOV A 
performed on this data is presented in Table 16. As may be seen in the left panel, 
pretreatment with neither cocaine nor U99 l 94A significantly affected subsequent 
sensitivity to a challenge injection of cocaine, cocaine effect: .E(l,28) <1.00; U99194A 
effect: ;E(l,28) < 1.36, g=0.253; U99194A x Cocaine interaction: !'.(1,28) =2.41, 
g=0.132; U99194A x Block: !'.(3,84) > 1.00. Compared with vehicle groups, the 
stereotypic counts of rats pretreated with cocaine appeared to decrease less across 
blocks, Cocaine x Block interaction: !'.(3,84) = 6.53, I!< .001; U99194A x Cocaine x 
Block interaction .E(3, 84) > 1.00. Thus, pretreatment with cocaine did not result in 
behavioral sensitization with stereotypic counts as a behavioral measure. 
Sensitization Test Session 9: U99194A Challenge Test 
Distance Traveled: 
Figure 17 displays the mean distance traveled for the four pretreatment groups 
after a l.Omg/kg dose ofU99194A. A summary of the ANOVA performed on this data 
is presented in Table 17. Overall, as may be seen in the left panel, prior treatment with 
cocaine significantly increased subsequent behavioral sensitivity to the activating 
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VEH-VEH VEH-COC U99194-VEH U99194-COC 15 30 45 60 
PRETREATMENT CONDITIONS BLOCKS OF 15 MINUTES 
EigUifL16. Mean stereotypic counts(± SEM) after a cocaine challenge injection (session 8) for rats prelliously treated 
chronically with either vehicle (VEH) or cocaine (15 mg/kg COC) in combination with either vehicle (VEH) or U99194A 
(1.00 mg/kg). The left panel represents the total session activity and the right panel presents the same data as a function 
offour 15 min blocks within the session 
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BLOCKS OF 15 MINUTES 
Eigure 17 Mean distance tra1.eled (± SEM) after a U99194A challenge injection (session 9) for rats previously treated 
chronically with either 1.ehicle (VEH) or cocaine (15 mg/kg COC) in combination with either 1.ehicle (VEH) or U99194A 
(1.00 rng/kg). The left panel represents the total session activity and the right panel presents the same data as a function 
of four 15 min blocks within the session 
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effects of the U99194A challenge injection, cocaine effect: ):(1,28) =14.33, 2<.001. 
More important, prior treatments with U99194A alone did not significantly increase 
subsequent sensitivity to U99194A, and did not affect the influence of prior cocaine 
treatments, U99194A effect: ):(1,28) < 1.00; U99194A x Cocaine interaction:):< 1.00. 
Rears: 
Figure 18 displays the mean number of rears for the four treatment groups after 
1.0 mg/kg dose ofU99194A. A summary of the ANOVA performed on this data is 
presented in Table 18. As may be seen in the left panel, pretreatment with cocaine 
significantly increased subsequent sensitivity to a challenge injection ofU99194A, 
cocaine effect: l:(1,28) = 11.65, 2<.0l, and this increase was not affected by concurrent 
U99194A pretreatment, U99194A effect: F(l,28)<1.00, U99194A x cocaine 
interaction: l:(1,28) =1.13, 2=0.296. However, as shown on the right panel, all groups 
decreased activity across blocks, block effect: ):(3,84) = 107.29, 2<.001, but there were 
no interactions between U99194A and block factors, U99194A x Block interaction: 
l:(3,84) =1.04, 2=0.378; Cocaine x Block interaction: ):(3,84) = 11.65, 2=,002; 
U99194A x Cocaine x Block interaction: ):(3,84)<1.00]. 
Stereotypy: 
Figure 19 displays the mean number of stereotypic counts for the four 
pretreatment groups after a l.0mg/kg dose ofU99194A. A summary of the ANOVA 
performed on this data is presented in Table 19. As may be seen in the left panel, 
pretreatment with cocaine increased the subsequent sensitivity to a challenge injection 
ofU99194A, but pretreatment with 1.0 mg/kg U99194A did not significantly affect 
subsequent sensitivity to a challenge injection ofU99194A, U99194A effect: 
l:(1,28)<1.00, cocaine effect: ):(1,28) =15.56, 2< .001. Pretreatment with U99194A did 
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not affect the stereotypic counts ofrats, U99194A x Cocaine interaction: E(l,28)<1.00. 
Stereotypic counts of all groups decreased across the blocks, block effect: E(3,84) 
=98.82, 2<.00 I. There were no interactions between U99194A and block, cocaine and 
block, U99194A, U99194A and cocaine factors, U99194A x Block interaction: E(3,84) 
< 1.00; Cocaine x Block interaction: ;E(3,48) =1.63, 2=0.189; U99!94A x Cocaine x 
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Consistent with previous research, with repeated daily treatment, cocaine produced 
a greater increase in both horizontal (distance traveled) and vertical (rearing) activity, 
as well as stereotypic small movements compared to vehicle injections ( e.g. Kalivas et 
al., 1988; Martin-Iverson & Reimer, 1994). Furthermore, repeated treatment with 
cocaine alone induced behavioral sensitization to horizontal locomotor-activating 
effects of cocaine, but not to rearing or stereotypic activity. This progressive increase in 
cocaine-induced locomotor activity is consistent with the sensitization effect previously 
reported for cocaine (e.g. Kalivas et al. 1988; Steketee, Striplin, Murray, & Kalivas, 
1991). 
In contrast to the cocaine-induced hyperactivity effect, U99194A treatments with 
both 0. lmg/kg and l .0mg/kg did not significantly affect horizontal locomotion, 
stereotypic activity or rearing. However, in a preliminary experiment in our laboratory, 
U99194A did produce a small, but significantly increase in activity when administrated 
five minutes before activity testing (Mattingly, Rice, Langfels, & Fields, 2000). Similar 
results were reported by other studies (Waters, Svensson, Hassdsma, Smith, & 
Carlsson, 1993; Gendreau, Petitto, Schnauss, Frantz, & Hartesveldt, 1997). U99194A 
increased locomotor behavior over a wide dose range in Water's study (7-55mg/kg) 
and in Gendreau's studies (5-30mg/kg). This discrepancy between the current study 
and these previous works is probably related to methodological differences. For 
example, in our previous study (Mattingly et al., 2000), U99194A was administrated 5 
min before activity testing. In contrast, U99194A was administrated 15 min before 
activity testing in the current experiments. Although U99194A did not significantly 
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increase activity in the present study, U99194A treatments did not inhibit locomotor 
activity. This finding contrast with previous research with dopamine DI- and D2- type 
antagonists which significantly suppress activity (Mattingly, et al.,1993,1994). The 
current finding, therefore, is consistent with the view that the functional role ofD3 
receptor differs from that of dopamine DI- and D2 receptors (Mattingly, et al. 1996, 
1998). IfU99194A affected D2- receptors then activity should have been decreased. 
In contrast to DI and D2 dopamine antagonists, U99194A did not significantly 
affect the acute cocaine-induced increase in locomotor activity. This result contrasts 
with the effects of more conventional dopamine DI-type (SCH23390) and D2-type 
(sulpiride, eticlopride et al.) receptor antagonists which decreased motor behavior over 
a wide dose range (Mattingly et al. 1993; Mattingly et al. 1996; Ferrari & Guiliani, 
1995). Consistent with this finding, repeated treatment with U99194A enhanced, rather 
than inhibited the locomotor activity effect of amphetamine (Waters et al., 1993). 
Moreover, the dopamine D3-preferring receptor agonists PD128907 and quinpirole 
have been reported to attenuate, rather than enhance, the locomotor activity effects of 
amphetamine (Deboer, Enrico, Wright, Wise, & Timmerman, 1997; Defonseca, Rubio, 
Calderyon, & Coob, 1995). Similarly, the selective D3 receptor agonist 7-OH-DPAT 
attenuates the stimulating effects of cocaine (Mattingly et al., In press). Taken together, 
these findings suggest that dopamine D3 receptors, unlike D 1- and D2-type receptors, 
may be inhibitory with respect to behavior (Waters et al., 1993). 
Based on the previous research, we hypothesized that stimulation of dopamine D3 
receptors may be critical to the development of behavioral sensitization to cocaine. 
This hypothesis was based primarily on the finding that concurrent treatments of a low 
dose of the selective dopamine D3 receptor agonist, 7-OH-DPATwith cocaine 
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enhances the development of behavioral sensitization to cocaine (Mattingly et al., in 
press). Based upon this finding, it was predicted that blocking dopamine D3 receptor 
with U99194A may prevent the development of behavioral sensitization to cocaine. 
This hypothesis was not supported. Neither dose ofU99194A affected the development 
of behavioral sensitization to cocaine as measured across sessions or on the cocaine 
challenge test. This finding suggests that the stimulation of dopamine D3 receptors is 
not critical to the development of cocaine-induced behavioral sensitization. This 
finding is consistent with previous research using dopamine D2-type receptor 
antagonists (Mattingly et al., 1994; Wolf, White, Nasser,Brooderson & Khansa, 1993), 
and suggests that stimulation of individual dopamine receptors is not necessary for the 
development of behavioral sensitization. Moreover, these results are consistent with the 
findings that although 7-0H-DPAT partially substitutes for cocaine in drug 
discrimination tests, U99194A does not block the 7-0H-DPAT substitution for cocaine 
(Baker, Svensson, & Garner, 1998). Thus, like behavioral sensitization, D3 receptor 
may not be important for the subjective effects of cocaine. 
Although repeated treatment with U99194A did not affect the development of 
behavioral sensitization to cocaine, chronic pretreatment with cocaine increased the 
activity response to the U99194A challenge injection. This finding suggests that 
dopamine D3 receptor function may be altered by chronic cocaine treatment. This 
result is consistent with the finding that dopamine D3 binding is significantly increased 
in human cocaine overdose victims (Staly & Mash, 1996). Moreover, this finding 
appears consistent with the view that postsynaptic D3 receptor may be inhibitory with 
respect to locomotor behavior (Svensson et al 1993; Waters et al., 1993). If so, then the 
increased activity observed in cocaine-pretreated rats may represent disinhibition. 
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Unfortunately, the validity of this interpretation cannot be determined with the present 
experimented design. That is, since cocaine-pretreated rats often display conditioned 
hyperactivity after vehicle injections (Durazzo, Gauvin, Goulden, & Briscoe, 1992; 
Nomikos & Spyraki,1988), the apparent U99194A-induced increase in activity may 
simply be due to conditioning response. It might be noted, however, that conditioning 
effects usually dissipate very quickly after the vehicle iajection. In contrast, the 
hyperactivity in cocaine-pretreated rats after the U99194A challenge injection was 
maintained across the four fifteen minute blocks. This finding suggests that the 
hyperactivity observed may not be due to conditioning effects. However, additional 
research is needed to clarify the interpretation of this finding 
In summary, the present results clearly demonstrate that concurrent treatment 
with U99!94A and cocaine does not prevent the development of behavioral 
sensitization to cocaine. This finding suggests that stimulation of dopamine D3 
receptor is not critical to the development of behavioral sensitization to cocaine. 
However, although U99 l 94A treatments did not block cocaine-induced behavioral 
sensitization, chronic cocaine treatments altered the responsiveness of rats to a 
U99 l 94A challenge injection. This finding tentatively suggests that dopamine D3 
receptor function may be altered by chronic cocaine treatments. Currently, the validity 
of this interpretation is unclear. In conclusion, to the extent that the development of 
behavioral sensitization is a valid model for the development of cocaine craving, then 
the present results along with previous findings questioned the importance of dopamine 
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Summary of Analysis of Variance Performed on Mean Distance Traveled during the 
Pretreatment Session in Experiment 1. 
Source Df MS F p 
Between Groups 
U99194A(U) 1 7.864 E+06 2.23 0.1467 
Cocaine (C) 1 7.443 E+o8 210.91 0.0001 ** 
UxC 1 5.486 E+06 1.55 0.2228 
Error 28 9.882 E+07 
Within Groups 
Session (S) 6 7.809 E + 06 8.92 0.0001 ** 
UxS 6 8.164 E + 05 0.93 0.4728 
CxS 6 1.445 E + 07 16.52 0.0001 ** 
UxCxS 6 7.416 E + 05 0.85 0.5350 
Error 168 1.470 E + 08 0.88 
Block (B) 3 9.558 E +07 336.06 0.0001 ** 
UxB 3 3.943 E+ 05 1.39 0.2526 
CxB 3 3.610 E + 07 126.94 0.0001 ** 
UxCxB 3 2.239 E+05 0.79 0.5044 
Error 84 4.937 E + 07 
SxB 18 3.892 E+05 3.97 0.0001 ** 
UxSxB 18 6.982 E+04 0.71 0.7993 
CxSxB 18 8.689 E+ 05 8.87 0.0001 ** 
UxCxSxB 18 8.179E+04 0.84 0.6589 
Error 504 4.937 E+ 07 
57 
Table 3 
Summary of Analysis of Variance Performed on Mean Number of Rears during the 
Pretreatment Session in Experiment I 
Source df MS F p 
Between Groups 
U99194A (U) 1 1.479 E +o2 0.01 0.9143 
Cocaine (C) I 6.534 E+o5 52.10 0.0001 ** 
UxC I 6.480 E +02 0.05 0.8218 
Error 28 1.254 E+o4 
Within Groups 
Session (S) 6 9.026 E +03 4.48 0.0003** 
UxS 6 9.385 E +o2 0.47 0.8328 
CxS 6 2.081 E +03 0.05 0.4054 
UxCxS 6 7.108E+o2 0.35 0.9074 
Error 168 2.014 E +o3 
Block (B) 3 2.077 E +o5 164.3 I 0.0001 ** 
UxB 3 l.348E+05 0.11 0.9560 
CxB 3 1.141 E+o4 9.02 0.0001 ** 
UxC-xB 3 1.437 E +o3 1.14 0.3389 
Error 84 1.264 E +o3 
SxB 18 2.220 E+o3 4.88 0.0091 ** 
UxSxB 18 1.872 E +o2 0.41 0.9856 
CxSxB 18 9.564E+o2 2.10 0.0052** 
UxCxSxB 18 2.443 E +o3 0.54 0.9407 
Error 504 4.552 E+o2 
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Table4 
Summary of Analysis of Variance Perfonned on Mean Stereotypic Counts during the 
Pretreatment Session in Experiment I 
Source df MS F p 
Between Groups 
U99194A(U) I 4.812 E+05 0.25 0.6224 
Cocaine (C) I 8.668 E+08 446.71 0.0001 ** 
UxC I 3.370 E + 04 0.02 0.8961 
Error 28 1.940 E + 06 
Within Groups 
Session (S) 6 1.570E+06 1.89 0.0858 
UxS 6 1.631 E + 06 2.03 0.0640 
CxS 6 7.397 E + 06 8.89 0.0001 ** 
UxCxS 6 1.083 E +06 1.30 0.2591 
Error 168 8.323 E+05 
Block (B) 3 9.595 E+07 314.55 0.0001 ** 
UxB 3 2.980 E+05 0.98 0.4076 
CxB 3 5.867 E + 06 19.23 0.0001 ** 
UxCxB 3 7.680 E +05 2.52 0.0636 
Error 84 3.050 E+05 
SxB 18 5.035 E+05 3.60 0.0001 ** 
UxSxB 18 7.147 E + 04 0.51 0.9535 
CxSxB 18 2.782 E + 05 1.99 0.0091 ** 
UxCxSxB 18 9.448 E+04 0.68 0.8368 
Error 504 1.399 E + 05 
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Table 5 
Summary of Analysis of Variance Performed on Mean Distance Traveled on the 
Cocaine (15mg/kg) Challenge Day of Experiment 1. 
Source df MS F p 
Between Groups 
U99194A(U) 1 2.827 E +o4 0.01 0.9099 
Cocaine (C) 1 4.725 E+07 21.79 0.0001 ** 
UxC 1 7.001 E +05 0.32 0.5744 
Error 28 6.071 E +o7 
Within Groups 
Blocks (B) 3 2.871 E+o7 149.05 0.0001 ** 
UxB 3 1.085 E +05 0.56 0.6406 
CxB 3 1.898 E +o6 9.86 0.0001 ** 
UxCxB 3 1.699 E +o4 0.09 0.9663 
Error 84 
Table 6 
Summary of Analysis of Variance Performed on Mean Number of Rears on the 
Cocaine (15mg/kg) Challenge Day of Experiment I. 
Source df MS F p 
Between Groups 
U99194A (U) I 2.008 E +03 0.31 0.5850 
Cocaine (C) 1 3.413 E +o3 0.52 0.4774 
UxC 1 4.430 E +o3 0.67 0.4189 
Error 28 6.581 E +3 
Within Groups 
Blocks (B) 3 2.314 E +o2 25.70 0.0001 ** 
UxB 3 5.622E+o2 0.62 0.6011 
CxB 3 1.497 E +o2 0.17 0.9189 
UxCxB 3 6.563 E +02 0.73 0.5374 




Summary of Analysis of Variance Performed on Mean Stereotypic Counts on the 
Cocaine (15mg/kg) Challenge Day of Experiment I. 
Source df MS F p 
Between Groups 
U99194A (U) 6.808 E+o4 0.06 0.8021 
Cocaine (C) 1 1.808 E +o6 1.70 0.2028 
UxC I 1.347 E +o5 0.13 0.7246 
Error 28 1.063 E+o6 
Within Groups 
Blocks (B) 3 1.233 E +o7 86.38 0.0001 ** 
UxB 3 1.153 E +o5 0.81 0.4931 
CxB 3 4.030 E +o5 2.82 0.0437* 
UxCxB 3 2.572 E +o5 1.80 0.1531 
Error 84 1.427 E +o5 
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Table 8 
Summary of Analysis of Variance Performed on Mean Distance Traveled on the 
U99194A (0. lmg/kg) Challenge Day in Experiment I. 
Source df MS F p 
Between Groups 
U99194A (U) 1 9.262 E+04 0.62 0.4377 
Cocaine (C) 1 2.918 E +06 19.53 0.0001 ** 
UxC 1 1.458 E+o4 0.10 0.7570 
Error 28 1494 E+05 
Within Groups 
Blocks (B) 3 4.330 E +o6 80.76 0.0001 ** 
UxB 3 7.703 E +o4 1.44 0.2379 
CxB 3 3.979 E+05 7.42 0.0002** 
UxCxB 3 2.227E+o4 0.42 0.7424 
Error 84 5.362 E +o4 
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Table 9 
Summary of Analysis of Variance Performed on Mean Number Rears on the U99194A 
(0.1 mg/kg) Challenge Day in Experiment I. 
Source df MS F p 
Between Groups 
U99194A(U) 1 8.778 E+0I 0.13 0.7204 
Cocaine (C) I 8.256E+o3 12.30 0.0016** 
UxC 6.125 E +02 0.91 0.3477 
Error 28 
Within Groups 
Blocks(B) 3 1.161 E+o4 44.II 0.0001 ** 
UxB 3 1.116 E +o2 0.42 0.7363 
CxB 3 3.521 E+o2 1.34 0.2676 
UxCxB 3 1.122 E +o2 0.43 0.7345 
Error 84 2.631 E+o2 
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Table 10 
Summary of Analysis of Variance Performed on Mean Stereotypic Counts on the 
U99194A (0.lmg/kg) Challenge Day in Experiment I. 
Source df MS F p 
Between Groups 
U99194A (U) I 6.010 E +05 1.15 0.2923 
Cocaine (C) 1 8.048 E+o6 15.43 0.0005** 
UxC 1 7.459 E +oz 0.00 0.9701 
Error 28 5.217 E +05 
Within Groups 
Blocks (B) 3 1.270 E +07 65.44 0.0001 ** 
UxB 3 1.513 E +05 0.78 0.5086 
CxB 3 1.991 E +o5 1.03 0.3855 
UxCxB 3 2.181 E +o4 0.11 0.9526 
Error 84 1.941 E +o5 
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Table 11 
Summary of Analysis of Variance Performed on Mean Distance Traveled During the 
Pretreatment Session in Experiment 2. 
Source Df MS F p 
Between Groups 
U99194A(U) 1 6.653 E+06 1.84 0.1850 
Cocaine (C) 1 5.616 E+08 155.61 0.0001 ** 
UxC 1 7.458 E+05 0.21 0.6529 
Error 28 3.609 E+06 
Within Groups 
Session (S) 6 3.364 E + 06 5.12 0.0001 ** 
UxS 6 3.142 E + 05 0.48 0.8242 
CxS 6 6.786 E+ 06 10.32 0.0001 ** 
UxCxS 6 1.883E + 05 0.29 0.9428 
Error 168 6.575 E + 05 
Block (B) 3 6.328 E + 07 177.56 0.0001 ** 
UxB 3 7.354 E +05 2.06 0.1112 
CxB 3 1.492E + 07 41.87 0.0001 ** 
UxCxB 3 2.239 E + 05 1.65 0.1851 
Error 84 4.937 E + 07 
SxB 18 1.656 E + 05 2.47 0.0007* 
UxSxB 18 5.642E+04 0.84 0.6509 
CxSxB 18 3.434 E + 05 5.12 0.0001 ** 
UxCxSxB 18 3.560 E + 04 0.53 0.9429 
Error 504 6.704 E+ 04 
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Table 12 
Summary of Analysis of Variance Performed on Mean Number of Rears during the 
Pretreatment Session in Experiment 2. 
Source df MS F p 
Between Groups 
U99194A(U) 1 7.018 E +o2 0.12 0.7345 
Cocaine (C) 1 1.165 E +o6 194.85 0.0001 ** 
UxC 1 6.103E+o4 10.21 0.0034** 
Error 28 5979 E+03 
Within Groups 
Session (S) 6 1.340 E +o4 3.06 0.0073** 
UxS 6 2.134 E +o3 0.49 0.8177 
CxS 6 5.445 E +o3 1.24 0.2873 
UxCxS 6 2.662 E+o3 0.61 0.7244 
Error 168 4.384 E +o3 
Block (B) 3 2.507 E +05 183.04 0.0001 ** 
UxB 3 1.341 E +o2 0.10 0.9610 
CxB 3 2.505 E+o4 18.29 0.0001 ** 
UxCxB 3 6.572 E+o3 0.48 0.6972 
Error 84 1.369 E +o3 
SxB 18 1.935 E +o3 3.92 0.0001 ** 
UxSxB 18 5.534 E+o2 1.12 0.3263 
CxSxB 18 l.032E+o3 2.09 0.0054** 
UxCxSxB 18 1.382 E +o2 0.28 0.9987 
Error 504 4.932 E +o2 
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Table 13 
Summary of Analysis of Variance Performed on Mean Stereotypic Counts During the 
Pretreatment Session in Experiment 2. 
Source df MS F p 
Between Groups 
U99194A (U) 1 4.527E+06 2.32 0.1388 
Cocaine (C) 1 9.952 E + 08 510.35 0.0001 ** 
UxC 1 7.591 E + 05 0.39 0.5377 
Error 28 1.950 E + 06 
Within Groups 
Session (S) 6 2.339 E + 06 3.45 0.0031 ** 
UxS 6 1.519 E + 05 0.22 0.9685 
CxS 6 3.811 E + 06 5.62 0.0001 ** 
UxCxS 6 3.137E+05 0.46 0.8351 
Error 168 6.780 E+05 
Block (B) 3 8.337 E + 07 237.16 0.0001 ** 
UxB 3 6.229 E + 05 1.77 0.1587 
CxB 3 5.248 E+06 14.93 0.0001 ** 
UxCxB 3 5.700 E+05 0.16 0.9215 
Error 84 3.515E + 05 
SxB 18 6.878 E+05 6.88 0.0001 ** 
UxSxB 18 8.833 E+ 04 0.88 0.5991 
CxSxB 18 1.697 E + 05 1.70 0.0362* 
UxCxSxB 18 l.007E+05 1.01 0.4490 
Error 504 9.996 E+04 
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Table 14 
Summary of Analysis of Variance Performed on Mean Distance Traveled on the 
Cocaine (15mg/kg) Challenge Day in Experiment 2. 
Source df MS F p 
Between Groups 
U99194A (U) I 1.081 E +o6 0.52 0.4789 
Cocaine (C) I 1.164 E +o8 55.44 0.0001 ** 
UxC I 2.067 E+o3 0.00 0.9572 
Error 28 2.099E+o6 
Within Groups 
Blocks (B) 3 9.918 E +06 76.92 0.0001 ** 
UxB 3 9.974E+04 0.77 0.5120 
CxB 3 4.007E+06 31.08 0.0001 ** 
UxCxB 3 6.206 E+04 0.48 0.6962 
Error 84 l.289E +05 
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Table 15 
Summary of Analysis of Variance Performed on Mean Number of Rears on the 
Cocaine (15mg/kg) Challenge Day in Experiment 2. 
Source df MS F p 
Between Groups 
U99194A (U) 1 1.922 E+o3 0.22 0.6444 
Cocaine (C) 1 5.806 E+o4 6.58 0.0160* 
UxC 1 1.320 E+o2 0.01 0.9035 
Error 28 8.827 E+o3 
Within Groups 
Blocks(B) 3 5.111 E +o4 33.15 0.0001 ** 
UxB 3 7.300 E +o2 0.47 0.7016 
CxB 3 1.524 E +o3 0.99 0.4022 
UxCxB 3 5.238 E+03 3.40 0.0215* 
Error 84 1.542 E +03 
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Table 16 
Summary of Analysis of Variance Performed on Mean Stereotypic Counts on the 
Cocaine (15mg/kg) Challenge Day in Experiment 2. 
Source df MS F p 
Between Groups 
U99194A (U) I 2.903 E+o6 1.36 0.2528 
Cocaine (C) I 8.187 E +o5 0.38 0.5402 
UxC 1 5.129 E +o6 2.41 0.1319 
Error 28 2.130 E +o6 
Within Groups 
Blocks (B) 3 8.331 E +o6 68.43 0.0001 ** 
UxB 3 9.823 E +o5 0.81 0.4935 
CxB 3 7.945 E+o5 6.53 0.0005** 
UxCxB 3 5.505 E+o5 0.45 0.7164 
Error 84 1.217 E +o5 
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Table 17 
Summary of Analysis of Variance Performed on Mean Distance Traveled on the 
U99194A (l.0mg/kg) Challenge Day in Experiment 2. 
Source df MS F p 
Between Groups 
U99194A (U) 1 2.105 E+o5 0.66 0.4248 
Cocaine (C) 1 4.597 E+06 14.33 0.0007** 
UxC I 1.414 E +o5 0.44 0.5122 
Error 28 3.209 E+o5 
Within Groups 
Blocks (B) 3 6.412 E +06 119.10 0.0001 ** 
UxB 3 4.207 E+o4 0.78 0.5076 
CxB 3 5.511 E +o4 1.02 0.3864 
UxCxB 3 3.746 E +o3 0.07 0.9760 
Error 84 5.383 E+o4 
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Table 18 
Summary of Analysis of Variance Performed on Mean Number Rears on the U99194A 
(l .0mg/kg) Challenge Day in Experiment 2. 
Source df MS F p 
Between Groups 
U99194A (U) 1 l.665E+o2 0.10 0.7535 
Cocaine (C) 1 1.931 E +o4 11.65 0.0020** 
UxC 1 1.876 E +o3 1.13 0.2964 
Error 28 1.657 E +o3 
Within Groups 
Blocks (B) 3 2.349 E +o4 107.29 0.0001 ** 
UxB 3 2.282E+o2 1.04 0.3781 
CxB 3 1.016 E +o3 4.64 0.0047** 
UxCxB 3 9.697 E +ol 0.44 0.7229 
Error 84 2.189 E +o2 
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Table 19 
Summary of Analysis of Variance Performed on Mean Stereotypic Counts on the 
U99194A (1.0mg/kg) Challenge Day in Experiment 2. 
Source df MS F p 
Between Groups 
U99194A(U) 1 2.938 E +o5 0.27 0.6081 
Cocaine (C) 1 1.699 E+o7 15.56 0.0005** 
UxC 1 l.026E +o6 0.94 0.3407 
Error 28 l.092E+06 
Within Groups 
Blocks(B) 3 2.035 E +o7 98.82 0.0001 ** 
UxB 3 6.273 E +o4 0.30 0.8219 
CxB 3 3.348 E+o5 1.63 0.1894 
UxCxB 3 1.751 E +o4 0.09 0.9680 





Squad# Subject# Pretreatment Group Chamber 
1 1 Vehicle-Vehicle 1 
1 2 Vehicle-Cocaine 2 
1 3 U99194A-Vehicle 3 
1 4 U99194A-Cocaine 4 
2 5 Vehicle-Cocaine 1 
2 6 Vehicle-Vehlcle 2 
2 7 U99194A-Cocaine 3 
2 8 U99194A-Vehicle 4 
3 9 U99194A-Vehicle 1 
3 10 U99194A-Cocaine 2 
3 11 Vehicle-Vehicle 3 
3 12 Vehicle-Cocaine 4 
4 13 U99194A-Cocaine 1 
4 14 U99194A-Vehicle 2 
4 15 Vehicle-Cocaine 3 
4 16 Vehicle-Vehicle 4 
5 17 Vehicle-Vehicle 1 
5 18 Vehicle-Cocaine 2 
5 19 U99194A-Vehicle 3 
5 20 U99194A-Cocaine 4 
6 21 Vehicle-Cocaine 1 
6 22 Vehicle-Vehicle 2 
6 23 U99 I 94 A-Cocaine 3 
6 24 U99194A-Vehicle 4 
7 25 U99194A-Vehicle 1 
7 26 U99194A-Cocaine 2 
7 27 Vehicle-Vehicle 3 
7 28 Vehicle-Cocaine 4 
8 29 U99 l 94A-Cocaine 1 
8 30 U99194A-Vehicle 2 
8 31 Vehicle-Cocaine 3 
8 32 Vehicle-Vehlcle 4 
